PRESS RELEASES

Humacyte is a privately held company that has raised approximately $480 million in equity and grants, including a $150 million investment from our strategic partner Fresenius Medical Care.  On February 17, 2021, Humacyte and Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement. 

Important Information About the Merger and Where to Find It:  A full description of the terms of the business combination is provided in a registration statement on Form S-4 filed with the SEC by AHAC that includes a prospectus with respect to the Combined Company’s securities to be issued in connection with the business combination and a proxy statement with respect to the shareholder meeting of AHAC to vote on the business combination. AHAC urges its investors, shareholders, and other interested persons to read the preliminary proxy statement/ prospectus as well as other documents filed with the SEC because these documents will contain important information about AHAC, Humacyte and the business combination. After the registration statement is declared effective, the definitive proxy statement/prospectus included in the registration statement will be mailed to shareholders of AHAC as of a record date to be established for voting on the proposed business combination. Shareholders will also be able to obtain a copy of the Form S-4, including the proxy statement/prospectus, and other documents filed with the SEC without charge, by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas, 5th Floor, New York, New York 10036. The preliminary and definitive proxy statement/prospectus to be included in the registration statement, can also be obtained, without charge, at the SEC’s website (www.sec.gov).

August 4, 2021

Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination

July 22, 2021

Humacyte Presents Potential of Functional Lung Engineering at Janelia R3 – Replace, Repair, Regenerate Planning Workshop

June 11, 2021

Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

June 10, 2021

Humacyte to Participate in Fireside Chat at Cowen 6th Annual FutureHealth Conference

June 08, 2021

Humacyte Presents In Vivo Data on Biovascular Pancreas Transplantation for Type 1 Diabetes Treatment

June 04, 2021

Humacyte to Provide Investor Update
on June 7

May 26, 2021

Humacyte Receives 2021 Life Sciences Award from Triangle Business Journal

May 22, 2021

Humacyte Announces Presentation by Principal Investigator Highlighting Clinical Experience with HAVs at Vascular Access Society of the Americas 2021 Spring Conference

May 21, 2021

Humacyte Presents Advances in Whole-Lung Engineering

May 19, 2021

Humacyte Appoints Dale Sander as Chief Financial Officer

May 06, 2021

Humacyte Leadership and Investigators to Present at Five Scientific Events in May

April 21, 2021

Humacyte Announces Positive Long-Term Follow-Up Data from Phase 2 Vascular Access Trial

April 14, 2021

Humacyte Secures $50 Million Debt Facility with Silicon Valley Bank

March 23, 2021

Humacyte CEO Dr. Laura Niklason and Alpha Healthcare CEO Rajiv Shukla to Present at CED Venture Connect 2021 Online Summit

March 11,2021

Humacyte to Present at Oppenheimer 31st Annual Healthcare Conference

March 5, 2021

Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021

February 17, 2021

Humacyte, a Transformative Biotechnology Platform Company Capable of Manufacturing Universally Implantable Bioengineered Human Tissue at Commercial Scale, Going Public via Merger with Alpha Healthcare Acquisition Corp.

January 12, 2021

Humacyte CEO Dr. Laura Niklason to Present Virtually at ICR Conference Jan 14

January 10, 2021

Humacyte CEO Dr. Laura Niklason to Present at J.P. Morgan Healthcare Conference January 11

Scroll to Top